{"id":"ccx354-c","safety":{"commonSideEffects":[{"rate":"null","effect":"Injection site reaction"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"IL-1RA is a naturally occurring protein that inhibits the pro-inflammatory effects of IL-1. By targeting IL-1RA, CCX354-C aims to reduce inflammation and potentially treat various inflammatory diseases.","oneSentence":"CCX354-C is a monoclonal antibody that targets the IL-1 receptor antagonist (IL-1RA) to prevent IL-1 mediated inflammation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T03:57:14.717Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of Still's disease"}]},"trialDetails":[{"nctId":"NCT01242917","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of CCX354-C in Subjects With Rheumatoid Arthritis Partially Responsive to Methotrexate Therapy","status":"COMPLETED","sponsor":"Amgen","startDate":"2010-09","conditions":"Rheumatoid Arthritis","enrollment":159},{"nctId":"NCT01027728","phase":"PHASE1, PHASE2","title":"Study to Evaluate Safety and Efficacy of CCX 354-C in Subjects With Rheumatoid Arthritis","status":"COMPLETED","sponsor":"Amgen","startDate":"2009-12","conditions":"Rheumatoid Arthritis","enrollment":24}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"CCX354-C","genericName":"CCX354-C","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CCX354-C is a monoclonal antibody that targets the IL-1 receptor antagonist (IL-1RA) to prevent IL-1 mediated inflammation. Used for Treatment of Still's disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}